Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?

AlphaStreet2021-06-30

The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

K21
2021-06-30
K21
Comment
Clemond
2021-06-30
Clemond
Cool.
Bhaga
2021-06-30
Bhaga
Comment
Muppy
2021-06-30
Muppy
Good
- Lmk:
  good
- Bhaga:
  Cool
ysg
2021-06-30
ysg
commentedddd
SillyOldBear
2021-06-30
SillyOldBear
Like and comment pls
- Muppy:
  good

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-06-30 09:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130740745","market":"us","top_or_hot":-1,"title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?","media":"AlphaStreet","content":"<div>\nThe company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so ...\n\n<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">网页链接</a>\n\n</div>\n","source":"lsy1609745492275","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/>AlphaStreet</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nThe company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so ...\n\n<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","article_id":"1130740745","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","pubTimestamp":1625017527,"columns":[],"sourceInfo":{"source_id":"lsy1609745492275","name":"alphastreet"},"weMediaInfo":null,"summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","collect":0,"end_time":0,"defaultTopTitle":"alphastreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Aerovate Therapeutics首次公开募股：这家生物技术公司上市后会面临什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTE":0.9},"content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":153616747,"gmtCreate":1625021151389,"gmtModify":1633945737022,"author":{"id":"3575778488052321","authorId":"3575778488052321","name":"K21","avatar":"https://static.tigerbbs.com/20b2e7b527356bdebb616c9b4167092c","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3575778488052321","idStr":"3575778488052321"},"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153616747","repostId":1130740745,"repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":" The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nAlphaStreet2021-06-30 09:45\n\n</h4>\n</header>\n<article>\n The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">AlphaStreet</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153613900,"gmtCreate":1625020959100,"gmtModify":1633945740580,"author":{"id":"3585169480050404","authorId":"3585169480050404","name":"Clemond","avatar":"https://static.tigerbbs.com/8bb44efb691fc17ac756757756f3732b","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3585169480050404","idStr":"3585169480050404"},"htmlText":"Cool.","listText":"Cool.","text":"Cool.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153613900","repostId":1130740745,"repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":" The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nAlphaStreet2021-06-30 09:45\n\n</h4>\n</header>\n<article>\n The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">AlphaStreet</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153633887,"gmtCreate":1625020531149,"gmtModify":1633945748523,"author":{"id":"3585145250045622","authorId":"3585145250045622","name":"Bhaga","avatar":"https://static.tigerbbs.com/8df89f7cbf6306c898f1bc0eef701a29","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3585145250045622","idStr":"3585145250045622"},"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153633887","repostId":1130740745,"repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":" The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nAlphaStreet2021-06-30 09:45\n\n</h4>\n</header>\n<article>\n The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">AlphaStreet</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153845909,"gmtCreate":1625019118701,"gmtModify":1633945775944,"author":{"id":"3578278614559162","authorId":"3578278614559162","name":"Muppy","avatar":"https://static.tigerbbs.com/51bd92f5e7a1327b1a0a9b7333dafa96","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3578278614559162","idStr":"3578278614559162"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/153845909","repostId":1130740745,"repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":" The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nAlphaStreet2021-06-30 09:45\n\n</h4>\n</header>\n<article>\n The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">AlphaStreet</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5076183,"gmtCreate":1625019641356,"gmtModify":1635240960223,"authorId":3575536975796198,"author":{"id":3575536975796198,"idStr":"3575536975796198","authorId":3575536975796198,"name":"Lmk","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153845909,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"},{"id":5076347,"gmtCreate":1625020521125,"gmtModify":1635240945611,"authorId":3585145250045622,"author":{"id":3585145250045622,"idStr":"3585145250045622","authorId":3585145250045622,"name":"Bhaga","avatar":"https://static.tigerbbs.com/8df89f7cbf6306c898f1bc0eef701a29","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153845909,"type":1,"supId":5076183,"prevId":0,"content":"Cool","text":"Cool","html":"Cool"}],"langContent":"EN"},{"id":153849967,"gmtCreate":1625018876859,"gmtModify":1631892575992,"author":{"id":"3575030506881099","authorId":"3575030506881099","name":"ysg","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3575030506881099","idStr":"3575030506881099"},"htmlText":"commentedddd","listText":"commentedddd","text":"commentedddd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/153849967","repostId":1130740745,"repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":" The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nAlphaStreet2021-06-30 09:45\n\n</h4>\n</header>\n<article>\n The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">AlphaStreet</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":153840419,"gmtCreate":1625018854031,"gmtModify":1633945780820,"author":{"id":"3559770113710833","authorId":"3559770113710833","name":"SillyOldBear","avatar":"https://static.tigerbbs.com/ef207140107fde8983f710c746a5b404","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3559770113710833","idStr":"3559770113710833"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153840419","repostId":1130740745,"repostType":4,"repost":{"id":"1130740745","kind":"news","pubTimestamp":1625017527,"share":"https://www.laohu8.com/m/news/1130740745?lang=zh_CN&edition=full","pubTime":"2021-06-30 09:45","market":"us","language":"en","title":"Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130740745","media":"AlphaStreet","summary":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to ","content":" The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>","source":"lsy1609745492275","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate Therapeutics IPO: What awaits the biotech firm after market debut?<blockquote>Aerovate Therapeutics IPO：上市后等待这家生物技术公司的是什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nAlphaStreet2021-06-30 09:45\n\n</h4>\n</header>\n<article>\n The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share. The IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.<blockquote>该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE；以每股13-15美元的价格发行约720万股股票。今年迄今为止，IPO市场延续了牛市，并未受到病毒相关不确定性的影响，其中科技和制药行业最引人注目。生物技术公司Aerovate Therapeutics，Inc.是最新一家准备上市的医疗保健公司。</blockquote> In a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.<blockquote>在提交给美国证券交易委员会的一份声明中，该公司透露计划在纳斯达克全球市场上市，股票代码为AVTE.它将以每股13-15美元的预计价格发行约720万股股票。杰富瑞集团和考恩是主要的账簿管理人。</blockquote> Cardiopulmonary Research<blockquote>心肺研究</blockquote> The Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.<blockquote>这家总部位于波士顿的制药商专注于罕见心肺疾病疗法的开发，由现任总裁本杰明·大可于2018年7月创立。这些业务由首席执行官蒂莫西·诺伊斯(Timothy Noyes)管理，他是默克(NYSE：MRK)的资深人士，上个月上任。</blockquote> The company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.<blockquote>该公司的主导项目涉及开发一种治疗肺动脉高压（PAH）的疗法。药，AV-101，是一种基于酪氨酸激酶抑制剂的吸入剂伊马替尼PAH是肺脉管系统的进行性增生性疾病，其特征在于小肺动脉的重塑、收缩和闭塞，导致高血压。</blockquote> <img src=\"https://static.tigerbbs.com/2ec3c278a5ee44a50959da085f9212b5\" tg-width=\"2048\" tg-height=\"1617\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> New-Gen Drug for PAH<blockquote>治疗PAH的新一代药物</blockquote> Early-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.<blockquote>早期临床试验表明，AV-101通过直接作用于疾病的病因，可有效治疗患有PAH的患者。在旨在评估该药物安全性和耐受性的II期试验中，将招募约200名患者。该研究的主要数据预计将于2023年中期公布。</blockquote> Proceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.<blockquote>即将发行的收益（价格范围的中点估计为1亿美元）将主要用于继续开发AV-101并支付与其商业发射相关的成本。一旦该药物在美国成功上市，管理层将寻求该药物的更多适应症，并通过挖掘新产品机会扩大产品线。本月早些时候，该公司以5600万美元的价格出售了约3000万股优先股。</blockquote> Risks<blockquote>风险</blockquote> It goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.<blockquote>不言而喻，最终临床试验的结果对于公司的未来至关重要。显然，该计划的主要风险是围绕COVID-19的不确定性——任何潜在的大流行死灰复燃都可能会推迟这一进程并导致成本上升。长期的成本压力可能会对公司的财务造成损害，该公司仅依赖于AV-101变得有利可图。此外，Aerovate必须与Verve Therapeutics等公司有效竞争，才能获得有意义的市场份额。</blockquote> Beingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.<blockquote>作为一家新兴业务，Aerovate尚未产生收入。2021财年，该公司净亏损333万美元，即每股13.79美元，而去年亏损961万美元，即每股40.31美元。这一改善反映了运营费用的下降，每年减少一半以上。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/\">AlphaStreet</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://news.alphastreet.com/aerovate-therapeutics-ipo-where-the-biotech-firm-is-headed-after-market-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130740745","content_text":"The company has revealed plans to list on the Nasdaq Global Market under the ticker symbol AVTE; to offer around 7.2 million shares for $13-15 per share.\n\nThe IPO market has continued the bull run so far this year, unfazed by the virus-related uncertainties, with thetechnology and pharma sectorsstealing the limelight mostly. Biotechnology company Aerovate Therapeutics, Inc. is the latest among the healthcare firms preparing to go public.\nIn a statement submitted to the Securities and Exchange Commission, the company revealed plans to list on the Nasdaq Global Market under the ticker symbolAVTE. It will beoffering about 7.2 million sharesat an estimated price of $13-15 per share. Jefferies Group and Cowen are the main book-running managers.\nCardiopulmonary Research\nThe Boston-based drug-maker, which is focused on the development of therapies for rare cardiopulmonary diseases, was founded in July 2018 by Benjamin Dake who currently serves as its president.The operations are managed by chief executive officer Timothy Noyes, a Merck (NYSE: MRK) veteran who assumed office last month.\nThe company’s lead program involves the development of a therapy for the treatment of pulmonary arterial hypertension (PAH). The medicine,AV-101, is an inhaler based on tyrosine kinase inhibitorimatinib. PAH is a progressive proliferative disease of the pulmonary vasculature that is characterized by remodeling, constriction, and occlusion of the small pulmonary arteries, leading to high blood pressure.\n\nNew-Gen Drug for PAH\nEarly-stage clinical trials have indicated thatAV-101is effective in treating patients suffering from PAH by acting directly on the cause of the disease.In phase-II of the trial — designed to assess the safety and tolerability of the drug — around 200 patients will be enrolled. The top-line data from the study is expected in mid-2023.\nProceeds from the upcoming offering – estimated at $100 million at the midpoint of the price range – will be used mainly for the continued development ofAV-101and to meet costs related to its commercial launch. Once it is successfully launched in the U.S, the management would pursue additional indications for the drug and expansion of the pipeline by tapping into new product opportunities. Earlier this month, the company sold around 30 millionpreferred sharesfor $56 million.\nRisks\nIt goes without saying that the outcome of the final clinical trial would be crucial as far as the company’s future is concerned. Obviously, the main risk to the program is the uncertainty surroundingCOVID-19— any potential resurgence of the pandemic might delay the process and lead to cost escalation.Prolonged cost pressures can take a toll on the finances of the company, which is dependent solely onAV-101to become profitable.Moreover, Aerovate will have to compete effectively with the likes of Verve Therapeutics to gain meaningful market share.\nBeingan emerging business, Aerovate is yet to generate revenue. In fiscal 2021, it incurred a net loss of $3.33million or $13.79 per share, compared to a loss of $9.61 million or $40.31 per share last year. The improvement reflects a dip in operating expenses, which more than halved annually.","news_type":1,"symbols_score_info":{"AVTE":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5076062,"gmtCreate":1625019127696,"gmtModify":1635240972245,"authorId":3578278614559162,"author":{"id":3578278614559162,"idStr":"3578278614559162","authorId":3578278614559162,"name":"Muppy","avatar":"https://static.tigerbbs.com/51bd92f5e7a1327b1a0a9b7333dafa96","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":153840419,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":90,"commentSize":12,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130740745","isCrawlerRequest":true}